The in-vitro and in-vivo inhibitory activity of biflorin in melanoma
By: Vasconcellos MC, Bezerra DP, Fonseca AM, Araújo AJ, Pessoa C, Lemos TL, Costa-Lotufo LV, de Moraes MO, Montenegro RC.

Faculdade de Ciências Farmacêuticas, Universidade Federal do Amazonas, Manaus, Amazonas Departamento de Fisiologia e Farmacologia, Faculdade de Medicina Departamento de Química Orgânica e Inorgânica, Universidade Federal do Ceará, Fortaleza, Ceará Departamento de Fisiologia, Universidade Federal de Sergipe, Sergipe, Aracajú eInstituto de Ciências Biológicas, Faculdade de Biotecnologia, Universidade Federal do Pará, Belém, Pará, Brazil.
Melanoma Res. 2011 Feb 19.

Abstract

Biflorin, an ortho-naphthoquinone, is an active compound found in the roots of Capraria biflora L. It has been reported that biflorin presents anticancer activity, inhibiting both tumor cell line growth in culture and tumor development in mice. The aim of this study was to examine the effectiveness of biflorin treatment using both in-vitro and in-vivo melanoma models. Biflorin displayed considerable cytotoxicity against all tested cell lines, with half maximal inhibitory concentration values ranging from 0.58 μg/ml in NCI H23 (human lung adenocarcinoma) to 14.61 μg/ml in MDA-MB-231 (human breast cancer) cell lines. In a second set of experiments using B16 melanoma cells as a model, biflorin reduced cell viability but did not cause significant increase in the number of nonviable cells. In addition, the DNA synthesis was significantly inhibited. Flow cytometry analysis showed that biflorin may lead to an apoptotic death in melanoma cells, inducing DNA fragmentation and mitochondria depolarization, without affecting membrane integrity. In B16 melanoma-bearing mice, administration of biflorin (25mg/day) for 10 days inhibited tumor growth,and also increased the mean survival rate from 33.3±0.9 days (control) to 44.5±3.4 days (treated). Our findings suggest that biflorin may be considered as a promising lead compound for designing new drugs to be used in the treatment of melanoma.

PMID: 21346641 [PubMed - as supplied by publisher] Source: National Library of Medicine.







Copyright 2026 InterMDnet | Privacy Policy | Disclaimer | System Requirements